- Home
- NPT vs KRRO Comparison
NPT vs KRRO Comparison
Compare NPT & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NPT | KRRO |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | China | United States |
| Employees | N/A | 87 |
| Industry | Specialty Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.5M | 105.0M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | NPT | KRRO |
|---|---|---|
| Price | $20.38 | $11.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $47.10 |
| AVG Volume (30 Days) | ★ 457.4K | 132.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.35 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,271,000.00 |
| Revenue This Year | N/A | $145.97 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.14 | $5.20 |
| 52 Week High | $22.38 | $55.89 |
Technical Indicators
Market Signals| Indicator | NPT | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 90.58 | 48.06 |
| Support Level | $4.42 | $10.55 |
| Resistance Level | N/A | $12.54 |
| Average True Range (ATR) | 1.91 | 0.78 |
| MACD | 1.59 | -0.15 |
| Stochastic Oscillator | 88.43 | 31.14 |
Price Performance
Historical ComparisonAbout NPT Texxon Holding Limited Ordinary shares
Texxon Holding Ltd provides technology-enabled supply chain management services to customers in the plastics and chemical industries in East China. The company operates through two segments: Supply Chain Trading and Plastic Manufacturing. Its services include procurement, logistics, payments, and fulfillment for Chinese SMEs, and all revenue is generated from operations within the People's Republic of China.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.